• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Breast cancer--influence of growth rate on prognosis and treatment evaluation: a study based on mastectomy scar recurrences.

作者信息

Pearlman A W

出版信息

Cancer. 1976 Oct;38(4):1826-33. doi: 10.1002/1097-0142(197610)38:4<1826::aid-cncr2820380460>3.0.co;2-l.

DOI:10.1002/1097-0142(197610)38:4<1826::aid-cncr2820380460>3.0.co;2-l
PMID:991096
Abstract

The growth rate of a mammary cancer can be calculated when a recurrence appears in the mastectomy scar. Growth rate can, at times, be approximated from the patient's history with reasonable accuracy. Approximately half of breast cancers exhibit rapid growth (tumor doubling time (Td), up to 25 days); one-third grow at an intermediate rate (Td 26 to 75 days) and 15% grow slowly (Td 76 days or longer). Anatomic (TNM) staging does not define a homogeneous patient group in breast cancer. Within each stage, there are rapid, intermediate, and slow-growing tumors. The prognosis varies importantly with the growth rate characteristics of the tumor. Survival is the product of the tumor doubling time and the number of tumor doublings through which the patient lives. Slowly growing and intermediate growth rate tumors are associated with a high percentage of 5-year survivors after mastectomy (between 80 and 100%). Rapidly growing tumors have few 5-year survivors. When survival after mastectomy is measured in the number of tumor doublings, the differences in survival of the three groups tended to disappear, indicating that in this select group of patients with scar recurrence there was no therapeutic advantage in any of the three groups, despite the differences in the survival times. The appreciable number of patients with tumors exhibiting slow or intermediate growth rates, in any series, suggests that the use of the 5-year interval is an inadequate measure of therapeutic response in breast cancer and may actually be misleading.

摘要

相似文献

1
Breast cancer--influence of growth rate on prognosis and treatment evaluation: a study based on mastectomy scar recurrences.
Cancer. 1976 Oct;38(4):1826-33. doi: 10.1002/1097-0142(197610)38:4<1826::aid-cncr2820380460>3.0.co;2-l.
2
Local recurrences following mastectomy: support for the concept of tumor dormancy.乳房切除术后局部复发:对肿瘤休眠概念的支持。
J Natl Cancer Inst. 1994 Jan 5;86(1):45-8. doi: 10.1093/jnci/86.1.45.
3
Locoregional recurrence of breast cancer: a retrospective comparison of treatment methods.乳腺癌的局部区域复发:治疗方法的回顾性比较
Neoplasma. 2002;49(6):426-31.
4
[Therapy and prognosis of small breast cancers. Comparison of subcutaneous mastectomy procedures with ablatio mammae].[小乳腺癌的治疗与预后。皮下乳房切除术与乳房切除手术的比较]
Geburtshilfe Frauenheilkd. 1990 Oct;50(10):754-70. doi: 10.1055/s-2008-1026360.
5
Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma.早期乳腺癌患者局部孤立性复发后死亡的预后因素
Cancer. 2002 Jun 1;94(11):2813-20. doi: 10.1002/cncr.10572.
6
Local recurrence of breast cancer: conventionally fractionated partial external beam re-irradiation with curative intention.局部复发性乳腺癌:常规分割部分外照射再放疗,有治愈意图。
Strahlenther Onkol. 2018 Sep;194(9):806-814. doi: 10.1007/s00066-018-1315-1. Epub 2018 May 23.
7
Local recurrence after mastectomy for breast cancer: analysis of clinicopathological, biological and prognostic characteristics.乳腺癌乳房切除术后局部复发:临床病理、生物学及预后特征分析
Breast Cancer Res Treat. 2007 Mar;102(1):61-73. doi: 10.1007/s10549-006-9310-0. Epub 2006 Jul 19.
8
Estimate of tumor growth time for breast cancer local recurrences: rapid growth after wake-up?乳腺癌局部复发肿瘤生长时间的估计:觉醒后快速生长?
Breast Cancer Res Treat. 1998 Sep;51(2):133-7. doi: 10.1023/a:1005887422022.
9
Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.在淋巴结阴性、HER2阳性乳腺癌女性患者中,根据局部治疗类型和曲妥珠单抗使用情况的局部区域复发及生存结果
Ann Surg Oncol. 2014 Oct;21(11):3490-6. doi: 10.1245/s10434-014-3767-6. Epub 2014 May 20.
10
Local recurrence after breast-conserving surgery and radiotherapy. Frequency, time course, and prognosis.
Cancer. 1989 May 15;63(10):1912-7. doi: 10.1002/1097-0142(19890515)63:10<1912::aid-cncr2820631007>3.0.co;2-y.

引用本文的文献

1
Breast Cancer Upstaging Risk and In Vivo Tumor Growth Rates Associated with Preoperative Delays.与术前延迟相关的乳腺癌分期升级风险及体内肿瘤生长速率
Ann Surg Oncol. 2025 Jul 23. doi: 10.1245/s10434-025-17867-9.
2
Management and outcomes of breast cancer patients with radiotherapy interruption.放疗中断的乳腺癌患者的管理与结局
Front Oncol. 2024 Jul 23;14:1337194. doi: 10.3389/fonc.2024.1337194. eCollection 2024.
3
A Mathematical Model to Predict Diagnostic Periods for Secondary Distant Metastases in Patients with ER/PR/HER2/Ki-67 Subtypes of Breast Cancer.
一种预测雌激素受体/孕激素受体/人表皮生长因子受体2/ Ki-67亚型乳腺癌患者继发性远处转移诊断期的数学模型。
Cancers (Basel). 2020 Aug 19;12(9):2344. doi: 10.3390/cancers12092344.
4
Treatment times in breast cancer patients receiving neoadjuvant vs adjuvant chemotherapy: Is efficiency a benefit of preoperative chemotherapy?新辅助化疗与辅助化疗的乳腺癌患者的治疗时间:术前化疗的优势是否在于提高效率?
Cancer Med. 2020 Apr;9(8):2742-2751. doi: 10.1002/cam4.2912. Epub 2020 Feb 25.
5
Cutaneous Metastasis after Surgery, Injury, Lymphadenopathy, and Peritonitis: Possible Mechanisms.手术后、损伤后、淋巴结病和腹膜炎的皮肤转移:可能的机制。
Int J Mol Sci. 2019 Jul 4;20(13):3286. doi: 10.3390/ijms20133286.
6
Consolidated mathematical growth model of the primary tumor and secondary distant metastases of breast cancer (CoMPaS).乳腺癌原发肿瘤和继发远处转移的综合数学生长模型(CoMPaS)。
PLoS One. 2018 Jul 6;13(7):e0200148. doi: 10.1371/journal.pone.0200148. eCollection 2018.
7
Timing and Delays in Breast Cancer Evaluation and Treatment.乳腺癌评估和治疗中的时间和延误。
Ann Surg Oncol. 2018 Oct;25(10):2829-2838. doi: 10.1245/s10434-018-6615-2. Epub 2018 Jul 2.
8
Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1).抗体药物偶联物临床转化的基于 PK-PD 建模与模拟的策略应用:以曲妥珠单抗-美坦新偶联物(T-DM1)为例。
AAPS J. 2017 Jul;19(4):1054-1070. doi: 10.1208/s12248-017-0071-y. Epub 2017 Apr 3.
9
Breast metastasis from vaginal cancer.阴道癌的乳腺转移
BMJ Case Rep. 2016 Jul 21;2016:bcr2016215895. doi: 10.1136/bcr-2016-215895.
10
In Vivo Tumor Growth Rate Measured by US in Preoperative Period and Long Term Disease Outcome in Breast Cancer Patients.超声测量乳腺癌患者术前体内肿瘤生长速率及长期疾病转归
PLoS One. 2015 Dec 10;10(12):e0144144. doi: 10.1371/journal.pone.0144144. eCollection 2015.